Skip to main content

Topline phase 3 ADAPT SERON results show IV efgartigimod significantly improved outcomes in seronegative myasthenia gravis, marking the first potential targeted therapy across MuSK+, LRP4+, and triple seronegative subtypes.:

Source: Neurology Read More